Tivic Health Systems, Inc. (TIVC)
NASDAQ: TIVC · Real-Time Price · USD
0.459
-0.051 (-9.92%)
At close: Feb 21, 2025, 4:00 PM
0.450
-0.009 (-2.05%)
After-hours: Feb 21, 2025, 7:59 PM EST
Company Description
Tivic Health Systems Inc. operates as a health tech company, focuses on developing and commercializing bioelectronic medicine.
Its primary product is ClearUP, a bioelectronic medicine for the treatment of sinus and nasal inflammation.
The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, such as BestBuy and FSAStore and through distributors.
Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California.
Tivic Health Systems, Inc.
| Country | United States |
| Founded | 2016 |
| IPO Date | Nov 11, 2021 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Jennifer Ernst |
Contact Details
Address: 25821 Industrial Boulevard, Suite 100 Hayward, California 94545 United States | |
| Phone | 888 276 6888 |
| Website | tivichealth.com |
Stock Details
| Ticker Symbol | TIVC |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001787740 |
| CUSIP Number | 888705100 |
| ISIN Number | US8887052095 |
| Employer ID | 81-4016391 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Jennifer Ernst | Co-Founder, Chief Executive Officer and Director |
| Dr. Blake Gurfein Ph.D. | Chief Scientific Officer |
| Lisa G. Wolf | Interim Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 12, 2025 | 8-K | Current Report |
| Feb 5, 2025 | 8-K | Current Report |
| Jan 3, 2025 | DEF 14A | Other definitive proxy statements |
| Jan 3, 2025 | 8-K | Current Report |
| Dec 23, 2024 | 8-K | Current Report |
| Dec 23, 2024 | PRE 14A | Other preliminary proxy statements |
| Dec 13, 2024 | 1-A/A | Filing |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | 8-K | Current Report |
| Nov 7, 2024 | 1-A/A | Filing |